相关实验视频

Updated: Sep 11, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

拜卡莱因通过抑制铁和调节肠道微生物群来改善小鼠DSS诱导的性结肠炎

Weiguang Lv¹, Shengnan Han¹, Ke Li¹

¹School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.

Frontiers in pharmacology

|August 18, 2025

概括

拜卡莱因通过减少炎症和氧化应激,在治疗性结肠炎 (UC) 中表现有前途. 这项研究表明baicalein.

科学领域:

胃肠病学和肝病学
药理学和毒理学药理学和毒理学
免疫学免疫学免疫学

背景情况:

性结肠炎 (UC) 是一种具有不清楚机制的慢性炎症性肠病.
拜卡莱因是一种天然化合物,对UC具有潜在的治疗价值,但其具体作用需要阐明.

研究的目的:

在小鼠模型中评估贝卡莱因对硫酸 (DSS) 诱导的UC的保护作用.
调查潜在的机制,包括氧化应激,炎症,铁亡和肠道微生物群调节.

主要方法:

使用4%的DSS溶液建立了一个UC小鼠模型.
通过口腔管通过口腔管进行baicalein (10和20 mg/kg) 和sulfasalazine (200 mg/kg) 的使用.
评估结肠损伤,炎症性细胞因子,氧化应激标志物,铁含量,蛋白质和基因表达,以及肠道微生物群组成 (16S rRNA测序).

主要成果:

拜卡莱因治疗显著改善了DSS诱导的UC症状,在高剂量组有显著的影响.
拜卡莱因降低了促炎性细胞因子 (TNF-α,IL-1β) 和氧化应激标志物 (Fe2+,MDA,ROS),同时增加了抗氧化剂标志物 (SOD,GSH).
拜卡莱因调节了与铁亡相关的蛋白质 (上调FTH1,GPX4,SLC7A11,SLC3A2,Nrf2;下调ACSL4) 并改变了肠道微生物群的组成,增加了有益细菌并减少了有害细菌.

结论:

拜卡莱因通过减轻炎症和氧化应激,显示出对实验性UC的显著保护作用.
该机制涉及抑制铁亡并恢复肠道微生物群平衡.
拜卡莱因代表了性结肠炎的潜在治疗剂.

关键词:

巴伊卡莱因 (Baicalein) 是一种植物.铁性化 (ferroptosis) 是一种我们的肠道微生物群.这是一种炎症炎症炎症炎症.氧化应激是一种氧化应激.性结肠炎是一种

更多相关视频

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...